Clinical Trials

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled

Vulvar Neoplasms

NCT05036681 2026-03-27

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma

9 enrolled 10 charts

Neoplasm Metastasis, Endometrial Neoplasms

NCT04919629 2026-03-23

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

60 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04430699 2026-03-19

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

24 enrolled

Vulvar Neoplasms

NCT06036836 2026-03-19

MK-4280A-010

163 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT05231122 2026-03-16

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04712851 2026-03-10

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

25 enrolled

Uterine Cervical Dysplasia

NCT01174121 2026-03-04

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05467670 2026-03-04

Safety and Efficacy of Anti-CD47, ALX148 in Combination With Liposomal Doxorubicin and Pembrolizumab in Recurrent Platinum-resistant Ovarian Cancer

16 enrolled

Ovarian Neoplasms

NCT06083844 2026-03-04

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT04781088 2026-02-11

Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

38 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05761951 2026-02-11

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Phase 2 Not yet recruiting

Endometrial Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

87 enrolled

Adenocarcinoma, Uterine Cervical Neoplasms

NCT07054567 2026-01-21

A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer

96 enrolled

Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

40 enrolled

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06640283 2025-12-24

ANA

GastrointestinalGynecologic

150 enrolled

Anal Canal Carcinoma, Uterine Cervical Neoplasms

NCT06266338 2025-12-22

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT07261683 2025-12-19

Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

20 enrolled

Ovarian Neoplasms

NCT05296512 2025-12-16

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

30 enrolled

Phase 2 Not yet recruiting

Ovarian Clear Cell Carcinoma

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

28 enrolled

Advanced Endometrial Cancer

NCT03797326 2025-11-17

LEAP-005

BreastCNSGastrointestinalGynecologic

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05256381 2025-11-17

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

GastrointestinalGynecologicThoracic

166 enrolled 43 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Ovarian Neoplasms, Colorectal Neoplasms

NCT06157151 2025-11-14

PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

46 enrolled

Uterine Cervical Neoplasms

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

35 enrolled

Uterine Cervical Neoplasms

NCT05263492 2025-10-02

Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer

4 enrolled 8 charts

Recurrence, Endometrial Neoplasms

NCT05446870 2025-10-01

MK-4830-002

160 enrolled 19 charts

Ovarian Neoplasms

NCT02628067 2025-09-22

KEYNOTE 158

EndocrineGastrointestinalGynecologicHead & NeckNETOther solid neoplasmThoracic

1,609 enrolled 9 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Anus Neoplasms, Bile Duct Neoplasms, Biliary Tract Neoplasms, Carcinoid Tumor, Uterine Cervical Neoplasms, Mesothelioma, Parotid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Vulvar Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Neuroendocrine Tumors, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03029403 2025-09-19

Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

47 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04387227 2025-09-18

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

22 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03108495 2025-09-17

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

210 enrolled

Uterine Cervical Neoplasms

NCT05903833 2025-09-09

PIERCE

42 enrolled

Vulvar Neoplasms

NCT05156268 2025-08-17

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05114421 2025-08-07

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

30 enrolled

High Grade Fallopian Tube Serous Adenocarcinoma

NCT03113487 2025-07-20

P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

29 enrolled 11 charts

Recurrent Platinum-Resistant Fallopian Tube Carcinoma

NCT02635360 2025-07-03

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

94 enrolled 16 charts

Uterine Cervical Neoplasms

NCT02899793 2025-06-11

Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

25 enrolled 15 charts

Endometrial Neoplasms

NCT02520154 2025-06-08

Pembrolizumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled 12 charts

Fallopian Tube Neoplasms

NCT04575961 2025-05-23

PERCEPTION

33 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Cystadenocarcinoma, Serous

NCT03835819 2025-05-15

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

18 enrolled 17 charts

Endometrial Neoplasms

NCT04483544 2025-04-29

Pembrolizumab and Olaparib in Cervical Cancer Patients

8 enrolled 13 charts

Uterine Cervical Neoplasms

NCT06502743 2025-04-03

PENELOPE

92 enrolled

Endometrial Neoplasms

NCT02644369 2025-03-26

INSPIRE

BreastDermatologicGynecologic

100 enrolled

Carcinoma, Ovarian Epithelial, Melanoma, Triple Negative Breast Neoplasms

NCT04357873 2025-02-19

PEVOsq

GastrointestinalGenitourinaryGynecologicHead & Neck

112 enrolled

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT06805864 2025-02-03

BROTHER

Phase 2 Not yet recruiting

45 enrolled